___

• 1. Kim SH, Jeong JB, Kim JW, Koh SJ, Kim BG, Lee KL, et al. Clinical and endoscopic characteristics of drug-induced esophagitis. World journal of gastroenterology. [Multicenter Study Observational Study]. 2014 Aug 21;20(31):10994-9. 2. Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. [Clinical Trial Research Support, Non-U.S. Gov't]. 2013 Mar;11(3):246-52 e1-5. 3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 2009 Sep 17;361(12):1139-51. 4. Shibagaki K, Taniguchi H, Goto D, Kobayashi K, Kinoshita Y. Dabigatran-induced asymptomatic esophageal mucosal injury. Gastrointest Endosc. [Case Reports]. 2016 Feb;83(2):472-3; discussion 4. 5. Liu E, Shehata M, Liu T, Amorn A, Cingolani E, Kannarkat V, et al. Prevention of esophageal thermal injury during radiofrequency ablation for atrial fibrillation. J Interv Card Electrophysiol. [Review]. 2012 Oct;35(1):35-44. 6. Ootani A, Hayashi Y, Miyagi Y. Dabigatran-induced esophagitis. Clin Gastroenterol Hepatol. [Case Reports]. 2014 Jul;12(7):e55-6. 7. Toya Y, Nakamura S, Tomita K, Matsuda N, Abe K, Abiko Y, et al. Dabigatran-induced esophagitis: The prevalence and endoscopic characteristics. J Gastroenterol Hepatol. 2016 Mar;31(3):610-4.